ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/SA/5042-Bedford-Park-Flinders-Medical-Centre
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
54
trial(s) found.
NCT07221357
Advanced
Phase 2 / Phase 3
Not yet recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06876662
Haem
Phase 4
Recruiting
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma (
2024-517760-29-00--27289
)
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06852222
Haem
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy (
cAMeLot-2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
KMT2A inhibitor
antimetabolite
placebo
Leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06710132
Advanced
Phase 1 / Phase 2
Recruiting
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol) (
MS202329-0010
)
anti-CEACAM5 antibody-drug conjugate
Gastric cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06697301
Advanced
Phase 2 / Phase 3
Recruiting
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006) (
EIK1001-006
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
placebo
Melanoma
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - Icon Cancer Care Chermside
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06690775
Advanced
Phase 2
Recruiting
Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6 (
TORL123-002
)
Dexamethasone
Filgrastim
Pegfilgrastim
glucocorticoid
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06669975
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors (
AP402-101
)
bispecific p95ERBB2/4-1BB antibody
bispecific p95ERBB2/CD137 antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor (
2024-515689-15-01--18877
)
BTK inhibitor
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Glandore - Ashford Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06578871
Radonc
Phase 2
Not yet recruiting
Surgery for the Unknown Primary in the Era of p16-positive Oropharyngeal Squamous Cell Carcinoma: Reducing Ionizing Radiation (
SUPERIOR
): A Randomized Trial
Intensity Modulated Radiotherapy
Radiotherapy
cancer therapy
Head and neck squamous cell carcinoma
Oropharyngeal squamous cell carcinoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06578247
Haem
Phase 3
Recruiting
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (
QuANTUM-WILD
)
FLT3 inhibitor
KIT inhibitor
placebo
Leukaemia
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT06499285
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW) (
2024-516009-22-00--KER-050-D301
)
modified ActRIIA ligand trap protein
placebo
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06290505
Radonc
Phase 2
Recruiting
PALEO
: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications
Carboplatin
Durvalumab
Paclitaxel
Radiotherapy
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,PD-L1-targeting
platinum-based antineoplastic agent
taxane
Oesophageal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06203210
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (
IDeate-Lung02
)
anti-B7H3 antibody-drug conjugate
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06174987
Advanced
Phase 3
Recruiting
A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) (
ROMast-001
)
Trastuzumab Deruxtecan
anti-ERBB2 antibody-drug conjugate
cancer therapy
cancer therapy,ERBB2-targeting
immuno-oncology therapy,ERBB2-targeting
Cancer
VIC
3168 - Clayton - Monash Medical Centre (WITHDRAWN)
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06162572
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Multicenter, Open-label Platform Study of Select Immunotherapy Combinations in Adult Participants With Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) With High PD-L1 Expression (
SPLFIO-174
)
Cemiplimab
S095018
S095024
S095029
anti-CD73 monoclona antibody
anti-NKG2A monoclona antibody
anti-PD-1 monoclonal antibody
anti-TIM3 monoclona antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Non-small cell lung cancer
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3844 - Traralgon - Latrobe Regional Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06127407
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen (
CHONQUER
)
IDH1 R132 inhibitor
placebo
Chondrosarcoma
NOT Dedifferentiated chondrosarcoma
NOT Mesenchymal chondrosarcoma
NOT Myxoid chondrosarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06117774
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy (
DeLLphi-306
)
bispecific T-cell engager,DLL3-targeting
placebo
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3168 - Clayton - Monash Medical Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06047080
Haem
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (
GO44145
)
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
anti-CD79b antibody-drug conjugate
bispecific T-cell engager,CD20-targeting
glucocorticoid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05951049
Haem
Phase 2
Recruiting
A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02 (
AT02-003
)
pan-amyloid-binding peptide fusion immunoglobulin
AL amyloidosis
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT05727904
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma (
IOV-MEL-301
)
anti-PD-1 monoclonal antibody
autologous tumor-infiltrating lymphocytes therapy
Melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05694936
Advanced
Phase 2
Recruiting
A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (
VADER
Study).
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05642780
Advanced
Phase 2
Recruiting
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (
SKB264-II-06
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05555732
Advanced
Phase 3
Recruiting
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (
DS1062-A-U303
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (TERMINATED)
NCT05410145
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (
D3S-001-100
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04623541
Haem
Phase 1
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma,Richter's transformation
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04613596
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (
CA239-0009
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Cancer Care Wollongong
ACT
2605 - Garran - The Canberra Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3168 - Clayton - Monash Medical Centre (WITHDRAWN)
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT04594642
Haem
Phase 1
Recruiting
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma (
D7400C00006
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
NOT Breast cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck cancer
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NCT04419649
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (
KER050-MD-201
)
modified ActRIIA ligand trap protein
Myelodysplastic syndrome
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04170283
Advanced
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VAL-083
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03229200
Haem
Phase 4
Enrolling by invitation
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. (
2016-004356-30--PCYC-1145-LT
)
BTK inhibitor
Leukaemia
Lymphoma
Solid tumour
NSW
2139 - Concord - Concord Repatriation General Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03093116
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (
TRIDENT-1
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse (COMPLETED)
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)
3002 - East Melbourne - Epworth Freemasons (COMPLETED)
SA
5042 - Bedford Park - Flinders Medical Centre (COMPLETED)
NCT02582697
Advanced
Phase 3
Recruiting
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)
ACTRN12624001067561
Advanced
Not Applicable
Not yet recruiting
Evaluate the effectiveness of implementing a supportive care navigation tool for people diagnosed with pancreatic cancer.
Pancreatic cancer
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12623001077651
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (
EMITT-1
)
ERAP1 inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001444875
Radonc
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3K alpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12621000273886
Curative
Phase 2
Recruiting
The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer -
ADELE
: a randomised phase 2 trial
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12616001021460
Curative
Phase 1
Not yet recruiting
A Phase I trial of Sodium Valproate/MetformIn Combination as neoadjuvant therapy for ProstatE canceR (
VIPER-1-trial
)
HDAC inhibitor
biguanide antihyperglycaemic agent
Prostate cancer
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12617001190392
Advanced
Phase 1 / Phase 2
Status unknown
An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (
PIT-Study
)
Tipiracil Hydrochloride
Trifluridine
anti-EGFR monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
topoisomerase inhibitor
Colorectal cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (46)
Not yet recruiting (5)
Enrolling by invitation (2)
Status unknown (1)
Recruitment Country and State
SA (53)
VIC (44)
NSW (43)
QLD (38)
WA (27)
NZ (12)
TAS (8)
ACT (4)
NT (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (10)
Phase 2 (15)
Phase 2 / Phase 3 (5)
Phase 3 (14)
Phase 4 (3)
Trial Type
Advanced (32)
Haem (13)
Radonc (4)
Curative (4)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
41%
PD-1
33%
BTK
11%
ERBB2
9%
EGFR
9%
PD-L1
7%
KRAS
7%
KRAS G12C
7%
PI3K alpha
7%
CD20
6%
mTOR
6%
mTORC1
6%
VEGF
4%
Bcl2
4%
TLR7/TLR8
4%
KIT
4%
PARP
4%
HDAC
4%
Trop2
4%
CDK4
4%
CDK6
4%
oestrogen axis
4%
PI3K
4%
PI3K delta
4%
mTORC2
4%
VEGFA
2%
DNA methyltransferase
2%
KMT2A
2%
CEACAM5
2%
4-1BB
2%
CD137
2%
FLT3
2%
DPD
2%
orotate phosphoribosyltransferase
2%
HRAS G12C
2%
NRAS G12C
2%
B7H3
2%
IDH1
2%
IDH1 R132
2%
DLL3
2%
CD79b
2%
STING
2%
amyloid
2%
AKT
2%
CDK7
2%
ER
2%
cereblon
2%
CD19
2%
TP53
2%
TP53 Y220C
2%
HPV-E6
2%
HPV-E7
2%
ATM
2%
FGFR1
2%
FGFR1/2/3
2%
FGFR2
2%
FGFR3
2%
FGFR4
2%
PDGFR
2%
RET
2%
VEGFR
2%
ALK
2%
ROS1
2%
TRK
2%
ERAP1
2%
CTLA4
2%
XPO1
2%
Facility
5042 - Bedford Park - Flinders Medical Centre (54)
3000 - Melbourne - Peter MacCallum Cancer Centre (22)
4102 - Woolloongabba - Princess Alexandra Hospital (18)
3168 - Clayton - Monash Medical Centre (15)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (14)
3128 - Box Hill - Box Hill Hospital - Eastern Health (14)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (14)
2050 - Camperdown - Chris O'Brien Lifehouse (13)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (13)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (12)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (10)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (10)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (9)
3066 - Epping - Northern Hospital (8)
6150 - Murdoch - Fiona Stanley Hospital (8)
2500 - Wollongong - Wollongong Hospital (8)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (8)
7000 - Hobart - Royal Hobart Hospital (8)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (7)
3199 - Frankston - Peninsula Health Frankston Hospital (7)
2170 - Liverpool - Liverpool Hospital (6)
2217 - Kogarah - St George Hospital (6)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (6)
3004 - Melbourne, Southbank - Alfred Health (6)
6009 - Nedlands - Linear Clinical Research (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2139 - Concord - Concord Repatriation General Hospital (5)
2640 - Albury - Border Medical Oncology Research Unit (5)
3065 - Fitzroy - St Vincent's Hospital Melbourne (5)
3021 - St Albans - Western Health - Sunshine Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (4)
2031 - Randwick - Prince of Wales Hospital (4)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (4)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
2200 - Bankstown - Bankstown-Lidcombe Hospital (3)
2605 - Garran - The Canberra Hospital (3)
4215 - Southport - Gold Coast University Hospital (3)
2485 - Tweed Heads - The Tweed Hospital (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2500 - Wollongong - Cancer Care Wollongong (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4032 - Chermside - The Prince Charles Hospital (2)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
6000 - Perth - Royal Perth Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
NZ.9016 - Dunedin - Dunedin Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
3630 - Shepparton - Goulburn Valley Health (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
5037 - Glandore - Ashford Cancer Centre (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
4350 - Toowoomba - Toowoomba Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
4215 - Southport - Tasman Oncology (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
6009 - Nedlands - One Clinical Research (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
3011 - Footscray - Footscray Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Leukaemia
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Gynaecological cancer
B-cell lymphoma
Carcinoma
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Gastroesophageal cancer
Melanoma
Ovarian cancer
Head and neck cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Breast cancer
Urogenital cancer
Gastric cancer
Pancreatobiliary cancer
Epithelial Ovarian Cancer
HPV-related cancer
HPV16-positive cancer
Head and neck squamous cell carcinoma
Viral-related cancer
Breast adenocarcinoma
Endometrial cancer
Pancreatic cancer
Fallopian tube cancer
Small lymphocytic lymphoma
Myelodysplastic syndrome
Myeloproliferative neoplasm
Hepatobiliary cancer
Oesophageal cancer
Sarcoma
Bladder cancer
Cervical cancer
Follicular lymphoma
Triple-negative breast cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Male genital cancers
Prostate cancer
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Oropharyngeal squamous cell carcinoma
Biliary tract cancer
Cholangiocarcinoma
Colorectal adenocarcinoma
Bone cancer
Chondrosarcoma
Mantle cell lymphoma
Skin cancer
Uveal melanoma
AL amyloidosis
Amyloidosis
Plasma cell disorder
Non-squamous non-small-cell lung cancer
ER-positive breast cancer
HR-positive breast cancer
Diffuse large B-cell lymphoma,Richter's transformation
HER2-negative breast cancer
HER2-positive breast cancer
Glioblastoma
Germ cell tumour
EGFR-mutant non-small cell lung cancer
Anaplastic astrocytoma
Low-grade glioma
Gastric adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Hepatocellular carcinoma
Endometrial stromal sarcoma
Leiomyosarcoma
Low-grade serous ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Primary fallopian tube serous carcinoma
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy